---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-112631"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T05:59:06.873848+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Theravance settles YUPELRI patent litigation with Teva; generic launch delayed to April 2039

## Summary
- Settlement with Teva resolves ANDA litigation; Teva gets license to launch generic on or after April 23, 2039.
- License is royalty-free, non-exclusive, non-sublicensable; subject to DOJ/FTC review and customary exceptions.
- Litigation against six other ANDA filers (Accord, Cipla, Eugia, Lupin, Mankind, Orbicular) remains pending.

## SEC filing metadata
- accession: 0001104659-23-112631
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465923112631/0001104659-23-112631-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465923112631/tm2329363d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-112631
- JSON: https://secwatch.observer/filing/0001104659-23-112631.json
- Plain text: https://secwatch.observer/filing/0001104659-23-112631.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.